BioLoomics has filed a notice of an exempt offering of securities to raise $9,999,936.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, BioLoomics is raising $9,999,936.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Douglas Chapnick played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About BioLoomics
BioLoomics, Inc. is a synthetic biology company building the next generation of high-throughput drug screening tools. Our single cell testing technology enables rapid discovery of fluorescent biosensors for new and old drug targets. With biosensor cell lines, drug targets can be measured at specific locations inside living cells, providing valuable kinetic and specificity insights without compromising the speed and scale demands of high-throughput drug discovery.
To learn more about BioLoomics, visit http://bioloomics.com/
Contact:
Douglas Chapnick, Chief Executive Officer
303-955-7982
https://www.linkedin.com/in/doug-chapnick-99b82a173/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.